AUTH/2235/5/09: ProStrakan’s Abstral ad implied faster onset (“Acts in minutes”) and breached an undertaking

📅 2009 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2235/5/09
PartiesCephalon/Director v ProStrakan
ProductAbstral (sublingual fentanyl citrate tablet)
Material/channelBMJ advertisement (18 April 2009), ref MO17/0134; date of preparation March 2009
Main claims at issue“To hell and back in minutes”; “Acts in minutes”; also “Dissolves in seconds. Acts in minutes”
SPC timing referenced by PanelRelief from 15 minutes after administration onwards (SPC 5.1); dosing guidance 15–30 minutes (SPC 4.2)
Applicable Code year2008
Breach clauses2, 3.2, 7.2, 9.1 and 25
Complaint received28 May 2009
Undertaking received3 July 2009
Appeal hearingNo appeal by either party; Panel referred to the Appeal Board
Appeal Board considerations23 July 2009; 24 February 2010; 22 July 2010
Interim case report published26 August 2009
Case completed22 July 2010
Sanctions appliedUndertaking received; Advertisement; Audit of company’s procedures; Re-audit

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • Cephalon complained about a revised UK promotional campaign for Abstral (sublingual fentanyl citrate tablet) issued by ProStrakan, following an earlier PMCPA ruling against a “from 10 minutes” pain relief claim (Case AUTH/2207/2/09).
  • The BMJ advertisement (18 April 2009; ref MO17/0134; date of preparation March 2009) used the headline “To hell and back in minutes” and the claim “Acts in minutes” (also used unreferenced in the strapline).
  • The Abstral SPC stated pain relief was shown from 15 minutes after administration onwards (SPC section 5.1) and dosing guidance referred to 15–30 minutes (SPC section 4.2).
  • The Panel considered that “in minutes” would commonly be read as less than 15 minutes (and potentially less than 10), especially alongside the wording “Dissolves in seconds. Acts in minutes” and the visual depiction of rapid relief.
  • Because the complaint alleged non-compliance with an earlier undertaking, the Director also pursued that aspect (Clauses 2 and 9.1 considered in addition to those cited by Cephalon).
⚖️

Outcome

  • The Panel ruled the claims were misleading and inconsistent with the SPC.
  • The Panel ruled the new claims were sufficiently similar to the previously ruled claim and therefore breached the undertaking.
  • The Panel considered the matter serious enough to report ProStrakan to the Code of Practice Appeal Board (Paragraph 8.2 of the Constitution and Procedure).
  • The Appeal Board required an Authority audit, then a re-audit; after the re-audit it decided no further action was required.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training